“protein-degradation” Archives

in
Entry Author Date Location
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More 10/02/20 National
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More 09/25/20 National
Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs 09/24/20 Boston
Kymera Therapeutics Unveils IPO Pitch for Protein Degradation 07/31/20 Boston
Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership 07/09/20 Boston
GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance 06/16/20 San Francisco
Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More 06/12/20 National
Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More 06/05/20 National
Vividion Gets $135M in Collaboration With Roche on Protein Degradation 05/20/20 San Diego
Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More 04/10/20 National
Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More 03/13/20 National
Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic 03/12/20 Boston
Plexium Debuts With $28M and a New Take on Protein Degradation Drugs 10/17/19 San Diego
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels 10/07/19 National
Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More 06/21/19 National
With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field 06/19/19 San Francisco
Bayer and Arvinas Join Forces in $115M Pharma & Ag Research Alliance 06/04/19 Boston
Vertex Continues Plan to Diversify, Strikes a $70M Pact With Kymera 05/15/19 Boston
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More 11/16/18 National
Kymera Adds $65M in New Funding and Eyes First Clinical Test 11/13/18 Boston
Six Life Science Firms Close Q3 with an IPO, More Are on the Way 09/28/18 Boston
Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs 08/30/18 San Francisco
Page 1 of 1